BioCentury
ARTICLE | Clinical News

Pradaxa dabigatran etexilate: Phase IV started

May 25, 2015 7:00 AM UTC

Boehringer began the open-label, international Phase IV RE-CIRCUIT trial to compare 150 mg Pradaxa twice daily vs. warfarin in about 724 patients. RE-CIRCUIT is part of Boehringer’s RE-VOLUTION clinical trial program, which will include 14 trials and over 55,000 patients. ...